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INTRODUCTION
Atopic dermatitis (AD) is a chronic inflammatory skin
disease with impaired cell-mediated immune function and
compromised skin barrier function. The incidence of AD is
generally considered to be increasing worldwide (1, 2).
The presence of a defect in cutaneous permeability barrier
function is generally viewed as a downstream consequence
of inflammation (‘‘inside-outside’’ hypothesis) (1). Yet, alter-
natively, it has been hypothesized that the xerosis and per-
meability barrier abnormality, or both could drive disease
activity in AD and other inflammatory dermatoses (‘‘outside-
inside’’ hypothesis) (3). The primary cytokines, such as, IL-
1a and IL-1b initiate the cytokine cascade in AD (4). IL-4
inhibits ceramide synthesis, and exogenous applications of
the IL-4 impede permeability barrier recovery after acute
perturbations (5, 6). Two members of human AMPs, hBD2
and hCAP18 (LL-37) are down-regulated in a Th2-depen-
dent fashion in AD. They are co-localized with lipids with-
in epidermal lamellar bodies before their secretion, hence
some hypothesized that these two functions could be linked,
and explored the relationship between the cutaneous perme-
ability and antimicrobial barriers (7-9). 
Recently, several studies have shown that permeability bar-
rier function and antimicrobial defense are not discrete but
rather regulated in parallel (7, 10, 11). However, there are no
reports confirming that the mechanism is working in patients
with AD. Here, we investigated whether restoration of per-
meability barrier is accompanied by the concomitant improve-
ment of antimicrobial defense in patients with AD. 
MATERIALS AND METHODS
Subjects
The diagnostic criteria for AD were established according
to Hanifin and Rajka (12). The study protocol was approved
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Changes of Antimicrobial Peptides and Transepidermal Water Loss
After Topical Application of Tacrolimus and Ceramide-dominant 
Emollient in Patients with Atopic Dermatitis
Increased transepidermal water loss (TEWL) and downregulated antimicrobial pep-
tides (AMPs) are observed in patients with atopic dermatitis (AD). Tacrolimus and
ceramide-dominant emollients are effective in the treatment of AD by preventing the
production of inflammatory cytokines and by correcting skin barrier dysfunctions,
respectively. Present study was designed to investigate the relationship between
antimicrobial and barrier factors by measuring the changes of AMPs and TEWL after
topical application of tacrolimus and ceramide-dominant emollient in the patients
with AD. A total of three patients with AD were treated with tacrolimus in one lesion
and ceramide-dominant emollient in another lesion for 4 weeks. RT-PCR and west-
ern blotting revealed that the mRNA and protein expression levels of hBD-2 and LL-
37 were increased on the both study sites. Immunohistochemical analysis showed
significant increase of AMPs and IL-1a, while, IL-4 was decreased on the both study
sites. The mean changes of TEWL and AMPs showed no statistical difference bet-
ween both sites. Tacrolimus and ceramide-dominant emollient influence on both
TEWL and AMPs expression in patients with AD, namely they have similar effects
on both of the two. This study shows that restoration of permeability barrier func-
tion is accompanied by the concomitant improvement of antimicrobial defense in
patients with AD. 
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by the Ethical Committee of Chung-Ang University Hos-
pital Institute Review Board (I2007014). Informed consents
were obtained from all subjects after they were fully informed
about the details and the potential risk of the study. The char-
acteristics of subjects are summarized in Table 1. Two, clini-
cally similar and symmetric lesions of the patients were select-
ed, after measuring transepidermal water loss (TEWL), punch
biopsies were performed on the involved skin of 3 patients
with AD. Thin layers of tacrolimus ointment 0.1% (Protopic)
and ceramide-dominant emollient (TriCeram) were applied
twice daily for 4 weeks, respectively. 
TEWL assessment
To assess epidermal permeability barrier function, we per-
formed measurements of TEWL, which have been utilized
to provide information about status of permeability barrier
under either normal, experimentally perturbed, or diseased
conditions. 
The published guidelines for the measurement of TEWL
were followed (13). In detail, all subjects’ conditions were first
stabilized for 15 to 20 min in a climate- and humidity-con-
trolled room. Ambient temperature ranged between 21℃
and 24℃, with a mean relative humidity of 45%. TEWL
was measured with a Tewameter TM 210 (Courage & Khaz-
aka, Cologne, Germany) and estimated over 2 representative
involved sites, tacrolimus-applied skin and emollient-applied
skin, respectively. 
Reverse transcription-polymerase chain reaction (RT-PCR)
The tissues from punch biopsy were cut by scissor. Total
RNA was isolated from skin using TRIZol reagent (Invit-
rogen, Carlsbad, CA, USA) after adding 1 mL of TRIZol
reagent. And the tissue was homogenized by homogenizer.
After 5 min at room temperature, 0.2 mL of chloroform per
1mL of TRIZol reagent was added. Tubes were shaken vig-
orously. The mixtures were centrifuged with 12,000 rpm at
4℃ for 20 min, the upper aqueous phase were transferred to
a fresh tube, and the same amount of 2-propanol was added.
After the mixture was incubated at 4℃ for 15 min, it was
centrifuged with 12,000 rpm for 15 min. The supernatant
was removed, then the RNA pellet was washed with 70%
ethanol and centrifuged with 12,000 rpm at 4℃for 15 min,
and briefly dried. The purified RNA was dissolved in DEPC-
DW. Total cellular RNA was reverse transcribed at 42℃ for
30 min in containing reverse trancriptase (TaKaRa, Shiga,
Japan), 10×buffer, 10 mM dNTP (dNTP mix), oligo dT
primer, RNase inhibitor, and 25 mM MgCl2.
RT-PCR analysis of LL-37 and hBD-2 mRNA using spe-
cific primers were performed.
We synthesized the PCR primer on the basis of GenBank
data. Primers were chemically synthesized by DNA synthe-
sizer (Pharmacia, Biogatan, Uppsala, Sweden). Their sequences
were as follows:
hBD-2 (128 bp),
5′ -ATC TCC TCT TCT CGT TCC TC-3′ (sense)
5′ -ACC TTCTAG GGC AAA AGA CT-3′ (anti-sense);
LL-37 (208 bp),
5′ -CTG ATG CCT CTT CCA GGT GT-3′ (sense)
5′ -GAG GGA GCC CTT TCT GAA TC-3′ (anti-sense);
GAPDH (593 bp),
5′ -CCA CCC ATG GCA AAT TCC ATG GCA-3′ (sense),
5′ -GGT GCT GCT TGT TAG GAG GTC AAG TAA
AGG GC-3′ (anti-sense).
Two mL of each cDNA sample from the RT-PCR was am-
plified by PCR in containing Taq polymerase (TaKaRa), 10
×buffer, 25 mM MgCl2 and 10 pM primer. 
Electrophoresis
The products were run in 1.5% agarose gel contain 1 mg
ethidium bromide per millimeter. Twenty mL of reaction mix-
ture was mixed with loading buffer, separated by electrophore-
sis for 15 min at 100 volts and visualized by UV transillu-
mination. PCR products of hBD-2 and LL-37 were normal-
ized with GAPDH by using densitometer (volume of hBD-
2/volume of GAPDH×100, volume of LL-37/volume of
GAPDH×100).
Western blotting 
The tissues were cut by scissor. Skin were lysed in a buffer
containing 50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.02%
sodium azide, 100 mg/mL phenylmethanesulfonyl fluoride,
1 mg/mL aprotinin, 1% Triton×100, the tissue was homog-
enized by homogenizer. After centrifuging with 12,000 rpm
at 4℃ for 30 min, the supernatant was transferred into new
tube, 30 mg of soluble protein were loaded in 15% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PA-
GE) with sample buffer containing 1 M Tris and 50% glyc-
erol. Samples were heated at 95℃for 5 min prior to gel load-
ing. For hBD-2 detection, separated protein on gel electro-
phoresis was transferred to nitrocellulose membrane (Osmon-
ics, Minnesota, MN, USA) at 0.16 A for 1 hr. The membrane
was washed 3 times with Tris-buffered saline Tween 20 (TBST),
and blocked with 5% skim milk for 1 hr at room tempera-
ture. Following this, the membrane was incubated overnight
SCORAD, Severity Scoring of Atopic Dermatitis.
Type
Sex/Age 
(yr)
Duration
(yr)
SCORAD
Biopsy
site
1 F/24 11 20.1 Popliteal 
2 M/22 15 29.5 Popliteal
3 F/14 7 23.1 Buttock
Table 1. Characteristics of subjects at study entry768 K.Y. Park, D.H. Kim, M.S. Jeong, et al.
at 4℃ with goat anti-hBD-2 polyclonal antibody (1:1,500
in 5% bovine serum albumin, SantaCruz, Delaware, CA,
USA) and goat anti-LL-37 polyclonal antibody (1:1,500 in
5% bovine serum albumin, SantaCruz, Delaware, CA) and
then washed 3 times with TBST. The secondary mouse anti-
goat peroxidase conjugated antibody (1:2,000 in blocking
solution, SantaCruz) was incubated for 1 hr at room temper-
ature. After washing with ECL solution (SantaCruz) for 3 min,
the membrane was then exposed to radiography film (Roche,
Indianapolis, IN, USA).
Immunohistochemistry (IHC)
IHC was carried out using tissue section of involved sites
of atopic patients. In brief, 4 mm thick sections were deparaf-
finized in xylene 2 times for 15 min each, and epitopes were
retrieved by autoclaving (60℃) for 1 hr in citrate-buffered
saline (pH 6.0). After 40 min of cooling at room temperature,
the activity of endogenous peroxidase was quenched by treat-
ment with 3% H2O2 in TBST for 10 min. The sections were
blocked with normal goat serum for 1 hr, and incubated with
mouse anti-human LL-37, hBD-2, IL-1a and IL-4 polyclonal
antibodies, respectively. After 5 washes with PBS, the sec-
tions were incubated with peroxidase conjugated goat anti-
mouse secondary antibody, FITC anti-mouse secondary anti-
body and color was developed with diaminobenzidine. Two
independent blind observers evaluated serial sections. For
quantitative analysis, the stained cells were counted in three
consecutive microscopic fields (×400). DTEWL, mean changes of TEWL before and after application.
Subjects
No.
Application
Before After
TEWL (g/hm
2)
DTEWL
1 Tacrolimus 60 46 14
Ceramide 60 44 16
2 Tacrolimus 55 31 24
Ceramide 46 30 16
3 Tacrolimus 36 21 15
Ceramide 34 21 13
Table 2. Comparison of mean TEWL levels between tacrolimus-
applied and emollient-applied lesion in AD
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Fig. 1. RT-PCR for expression of hBD-2 and LL-37 before and after application of tacrolimus and ceramide-dominant emollient. (A) Increased
expression of hBD after application of tacrolimus and ceramide-dominant emollient. (B) Increased expression of LL-37 after application of
tacrolimus and ceramide-dominant emollient (*P<0.05). (C) No statistical difference of hBD-2 between tacrolimus-applied and emollient-
applied skin. (D) No statistical difference of LL-37 between tacrolimus-applied and emollient-applied skin. Pt., patient. Changes of AMPs and TEWL by Tacrolimus and Ceramide 769
Statistical analysis
Statistical analysis was conducted using Wilkoxon T test.
Statistical differences in mRNA expression or protein stain-
ing of hBD-2 and LL-37 between groups were determined,
with significant differences conferred when P≤0.05.
RESULTS
TEWL before and after application of tacrolimus and
ceramide-dominant emollient
For comparison of TEWL levels between tacrolimus-ap-
plied and emollient-applied skin in atopic patient, measure-
ments were performed 5 times for each site, repeatedly. The
mean TEWL levels decreased on the both sites. The mean
changes of TEWL were 17.7 g/hm2 (14-24 g/hm2) for tac-
rolimus-applied lesions and 15 g/hm2 (13-16 g/hm2) for
emollient-applied lesions, but there is no statistical differ-
ence between tacrolimus-applied and emollient-applied skin
(Table 2).
Expression of LL-37 and hBD-2 before and after 
application of tacrolimus and ceramide-dominant 
emollient using RT-PCR method
The expressions of hBD-2 and LL-37 mRNA were increas-
ed on the both sites after application of either tacrolimus or
ceramide-dominant emollient. The mean changes of AMPs,
however, showed no statistical difference between tacrolimus-
applied and emollient-applied skin (Fig. 1).
Expression of LL-37 and hBD-2 before and after 
application of tacrolimus and ceramide-dominant 
emollient using Western blotting
The expressions of hBD-2 and LL-37 proteins were increased
on the both sites after application either tacrolimus or cera-
mide-dominant emollient. The mean changes of AMPs, how-
ever, showed no statistical difference between tacrolimus-
applied and emollient-applied skin (Fig. 2).
Actin 42 
kDa
hBD-2 7 
kDa
Pt.1 Pt.2 Pt.3 Pt.1 Pt.2 Pt.3
Tacrolimus Ceramide A
Actin 42 
kDa
LL-37 18 
kDa
Pt.1 Pt.2 Pt.3 Pt.1 Pt.2 Pt.3
Tacrolimus Ceramide B
Fig. 2. Western blotting for expression of hBD-2 and LL-37 before
and after application of tacrolimus and ceramide-dominant emol-
lient. (A) Increased expression of hBD after application of tacro-
limus and ceramide-dominant emollient. (B) Increased expres-
sion of LL-37 after application of tacrolimus and ceramide-domi-
nant emollient.
Fig. 3. Immunohistochemical staining for hBD-2 and LL-37 in section from patients with atopic dermatitis. Expression of hBD-2, LL-37, IL-1a
and IL-4 receptors before and after tacrolimus and ceramide treatments as assessed by immunohistochemistry. Y axis: numbers of stained
cells in microscopic fields (×400).
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IHC for LL-37, hBD-2, IL-1a, and IL-4 before and after
application of tacrolimus and ceramide-dominant emollient
The intensity of staining of LL-37, hBD-2 were significant-
ly stronger in the epidermis after application on the both sites.
And the intensity of staining of IL-4 was slightly weaker in
the papillary dermis after application (Fig. 3).
DISCUSSION
Although both patients with AD and psoriasis have altered
skin barrier function, patients with psoriasis are more resis-
tant to skin infection; about 30 percent of patients with AD
have bacterial or viral infections of the skin, as compared with
only 7 percent of patients with psoriasis (14, 15). In psoriatic
skin, keratinocytes are rapidly proliferating and differentiat-
ing, making epidermis thickened. So, quantitatively, abun-
dant antimicrobial peptides are expressed in the psoriatic epi-
dermis (15, 16). A deficiency in the expressions of AMPs in
AD may account for the susceptibility of AD patients to skin
infection, such as Staphylococcus aureus (9). The inability to
increase AMPs may be due to suppression by Th2 cytokines
that are elevated in AD. In fact, in vitro keratinocytes in cul-
ture could be shown to lose that ability to increase hBD-2
expression when exposed to IL-4 or IL-13 (17, 18). Enhanced
Th2 cell activity is a hallmark of acute AD (17). Increased
production of IL-4, IL-5, and IL-13 by Th2 cells, in turn, inhib-
it Th1 cytokine production, including IFN-gand IL-18, which
are two beneficial mediators of AMPs. IL-4, IL-13 have also
direct inhibitory effects for AMPs expression (19, 20).
When emollients or moisturizers are used in the treatment
of AD and other inflammatory dermatoses, the intended aim
is limited to an improvement in skin hydration and mitiga-
tion of the xerosis. No reduction in inflammatory disease activ-
ity is expected, and such activity has been documented only
infrequently (21). However, Chamlin et al. (22) reported that
ceramide-dominant, barrier repair lipids alleviate childhood
atopic dermatitis, and attribute the improvement seen in their
patients to a normalization of barrier function. The normal-
ized barrier function, however, dampened the cytokine cas-
cade that initiates and sustains AD. It implied that emollients
are helpful in not only skin hydration but also ceasing to cyto-
kine cascade leading to inflammation through normalization
of permeability barrier function. 
Various immunological parameters are affected in patients
with AD: the relative and absolute numbers of circulating T
cells are reduced; lymphocyte response to mitogens are im-
paired; the cytotoxic potential of several cell types, such as
monocytes and natural killer cells, is decreased; and chemotat-
ic responsiveness is reduced (17, 20). There are few published
data on the effect of tacrolimus ointment on these parame-
ters, although Nghiem et al. (23) have shown that topical
calcineurin inhibitors specifically target key immunological
mechanisms that have been implicated in the pathogenesis
of AD, and act primarily on T cells in lesional skin. Failure
of AMPs to up-regulate appropriately in AD is attributed
currently to excess Th2 cytokines (9). Tacrolimus suppresses
Th2 activity and increases AMPs in AD. Although Kis et al.
(24) showed no effect on the IL-1a, IL-8, and TNF-a produc-
tion by tacrolimus in normal human keratinocytes, it is regard-
ed as being fundamental immunologic differences between
normal and atopic conditions. 
While levels of the IL-1a generally increase in inflamma-
tory dermatoses, they showed paradoxical decline in AD epi-
dermis (25). Recently, Elias et al. (4) proposed the hypothe-
sis that increase in serine protease activity would generate
active forms of IL-1, which is a primary contributor to inflam-
mation in AD. However, the results in this study support
the opposite conclusion about the cytokine milieu of AD;
elevated skin production of Th2 cytokines and low levels of
proinflammatory cytokines, such as, TNF-a, IFN-g, and IL-
1. And it is also reported that IL-13 and IL-4 inhibited TNF-a
and IFN-g-induced hBD-3 production (20). 
The antimicrobial barrier is intimately linked to the per-
meability barrier, and as with water egress, pathogen ingress
occurs through the extracellular domains (7). We investigat-
ed whether improvement of antimicrobial defense by tacro-
limus could simultaneously restored permeability barrier,
and the study yielded the expected results. There are several
reports supporting the hypothesis that the permeability and
antimicrobial barriers of the skin may not be discrete, but
rather co-regulated and even inter-dependent (7, 11). The
intimate link between these two functions is likely originat-
ed from the co-assembly of AMP with barrier lipid precur-
sors within nascent lamellar body (7, 8). The metabolic res-
ponse of AMP parallels the metabolic response of the lipid
to acute disruption of permeability barrier. When the per-
meability barrier is perturbed by solvent treatment or tape
stripping, a sequential, lipid-synthetic response ensues in
the underlying epidermis that rapidly restores normal per-
meability barrier homeostasis (26). Permeability disruption
not only removes lipid, but it also initiates a concomitant
and rapid loss of AMP from stratum corneum (4). Accord-
ing to the ‘outside-inside’ hypothesis, the barrier abnormal-
ity first provokes and sustains AD through activation of an
epidermis-initiated cytokine cascade, followed by recruit-
ment of the specific immunologic response (3). 
This study showed that ceramide-replacement improved
not only permeability barrier function but also antimicro-
bial barrier in AD; meanwhile tacrolimus-application im-
proved permeability barrier in addition to antimicrobial bar-
rier. In summary, the restoration of permeability barrier leads
the recovery of antimicrobial barrier, and the recovery of anti-
microbial barrier leads the restoration of permeability barri-
er. Through the present study, we could support the theory
about interrelationship between antimicrobial barrier and
permeability barrier in AD patient. Yet, further studies aboutChanges of AMPs and TEWL by Tacrolimus and Ceramide 771
the intermediate process linking antimicrobial barrier to per-
meability barrier (e.g., inflammatory cells, cytokines, skin
pH, filaggrin, serine protease) are required. 
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